Unlike everyday supplements stocked in every health store, CJC-1295 reaches researchers through a dedicated online market that Kemi residents navigate through international suppliers. This matters because CJC-1295 quality ranges widely across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor controls every quality variable. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. The sections below cover what Kemi researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Kemi researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Quality CJC-1295 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are signalling genuine quality commitment. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Kemi
COA-verified · International tracking · Research grade
All use of CJC-1295 in Kemi or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the specific protection against this risk. The research literature on CJC-1295 should be read critically before planning any study — study approaches, dose levels, and measured endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
